These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15190302)

  • 1. Antiplatelet agents.
    Cattaneo M
    Hematol J; 2004; 5 Suppl 3():S170-4. PubMed ID: 15190302
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiplatelet agents.
    Varon D; Spectre G
    Hematology Am Soc Hematol Educ Program; 2009; ():267-72. PubMed ID: 20008209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of platelets in peripheral arterial disease: therapeutic implications.
    Matsagas MI; Geroulakos G; Mikhailidis DP
    Ann Vasc Surg; 2002 Mar; 16(2):246-58. PubMed ID: 11972262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. Part I: Concept of resistance.
    Vadász D; Sztriha LK; Sas K; Vecsei L
    Ideggyogy Sz; 2012 Nov; 65(11-12):377-85. PubMed ID: 23289172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
    Tetik S; Ak K; Isbir S; Eksioglu-Demiralp E; Arsan S; Iqbal O; Yardimci T
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):189-98. PubMed ID: 19703819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.
    Angiolillo DJ
    Diabetes Care; 2009 Apr; 32(4):531-40. PubMed ID: 19336638
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
    van Werkum JW; Topcu Y; Postma S; Kelder JC; Hackeng CM; ten Berg JM; Verheugt FW
    Thromb Haemost; 2008 Mar; 99(3):637-9. PubMed ID: 18327417
    [No Abstract]   [Full Text] [Related]  

  • 8. Proposal of a "gradient model" to evaluate residual platelet activity on antiplatelet therapy: A pilot study.
    Lelli N; Rizkallah R; Ferrari P; Pedretti S; Cariani E; Trenti T
    Thromb Res; 2017 Feb; 150():19-21. PubMed ID: 27992784
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiplatelet agents and arterial thrombosis.
    Billett HH
    Cardiol Clin; 2008 May; 26(2):189-201, vi. PubMed ID: 18406994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute coronary syndrome: are intervention and IIb/IIIa platelet inhibitors epiphenomena?
    Jackson G
    Int J Clin Pract; 2001; 55(6):351-2. PubMed ID: 11501219
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmazie in unserer Zeit 4/2009].
    Alban S; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):295. PubMed ID: 19572344
    [No Abstract]   [Full Text] [Related]  

  • 12. The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome.
    Gurbel PA; Tantry US
    J Interv Cardiol; 2008 Dec; 21 Suppl 1():S10-7. PubMed ID: 19090932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
    Otterstad JE; Brosstad F
    Scand Cardiovasc J; 2004 Mar; 38(1):9-15. PubMed ID: 15204241
    [No Abstract]   [Full Text] [Related]  

  • 14. Update on clinical trials of antiplatelet therapy for cerebrovascular diseases.
    Bhatt DL; Kapadia SR; Yadav JS; Topol EJ
    Cerebrovasc Dis; 2000; 10 Suppl 5():34-40. PubMed ID: 11096181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New thoughts on strategies for modulating platelet function through the inhibition of surface receptors.
    Nurden AT
    Haemostasis; 1996 Oct; 26 Suppl 4():78-88. PubMed ID: 8979114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring antiplatelet drug effects in the laboratory.
    Harrison P; Frelinger AL; Furman MI; Michelson AD
    Thromb Res; 2007; 120(3):323-36. PubMed ID: 17239428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
    Prescrire Int; 2009 Dec; 18(104):272-3. PubMed ID: 20027714
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability of response to antiplatelet therapy: what should we do next?
    Shantsila E; Lip GY
    Fundam Clin Pharmacol; 2009 Feb; 23(1):19-22. PubMed ID: 19267768
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiplatelet agents for stroke prevention.
    Paciaroni M; Gallai V
    Cerebrovasc Dis; 2000; 10 Suppl 4():36-9. PubMed ID: 11070399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.